- All > Medicine Access and Rational Use > Better Medicines for Children
- All > Medicine Access and Rational Use > Selection
- Keywords > Essential Medicines List (EML)
- Keywords > Essential Medicines List for children - EMLc
- Keywords > medicines utilization
- Keywords > paediatric medicines
- Keywords > use of medicines
- Keywords > WHO expert committee
- Keywords > WHO Model List of Essential Medicines
- Keywords > médicaments pédiatriques
- Keywords > medicamentos pediátricos
- Keywords > uso de medicamentos
(2019; 32 pages)
This Summary reports the recommendations made by the WHO Expert Committee on the Selection and Use of Essential Medicines for the 2019 Essential Medicines Lists update.
The 22nd meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines took place in Geneva, Switzerland, from 1 to 5 April 2019. The aim of the meeting was to review and update the 20th WHO Model List of Essential Medicines (EML) and the 6th WHO Model List of Essential Medicines for Children (EMLc).
The Expert Committee considered 65 applications, including proposals to add 53 new medicines and new formulations of 19 existing medicines, extend the indications for 34 listed medicines, and to remove 10 medicines or formulations from the lists. The Expert Committee also considered reports and recommendations from the EML Antibiotics and Cancer Medicines Working Groups. In accordance with applicable procedures, the Expert Committee evaluated the scientific evidence for the comparative effectiveness, safety and cost-effectiveness of the medicines in question.
In summary, the Expert Committee:
- recommended the addition of 28 new medicines to the EML (12 to the core list and 16 to the complementary list);
- recommended the addition of 23 new medicines to the EMLc (6 to the core list and 17 to the complementary list);
- recommended the addition of new formulations of 16 currently listed medicines;
- recommended adding additional indications for 26 currently listed medicines;
- recommended the deletion of 9 medicines and of specific formulations of a further 4 medicines; and
- rejected 21 applications for inclusion, change or deletion of 31 medicines.
The recommendations are briefly described below in order of their appearance on the Model Lists according to the classification.
A full summary of changes to the Model Lists is shown in Table 1. The applications not recommended are listed in Table 2.